Nature Communications (Dec 2022)
Tissue and liquid biopsy profiling reveal convergent tumor evolution and therapy evasion in breast cancer
- Smruthy Sivakumar,
- Dexter X. Jin,
- Hanna Tukachinsky,
- Karthikeyan Murugesan,
- Kimberly McGregor,
- Natalie Danziger,
- Dean Pavlick,
- Ole Gjoerup,
- Jeffrey S. Ross,
- Robert Harmon,
- Jon Chung,
- Brennan Decker,
- Lucas Dennis,
- Garrett M. Frampton,
- Luciana Molinero,
- Steffi Oesterreich,
- Jeffrey M. Venstrom,
- Geoffrey R. Oxnard,
- Priti S. Hegde,
- Ethan S. Sokol
Affiliations
- Smruthy Sivakumar
- Foundation Medicine, Inc.
- Dexter X. Jin
- Foundation Medicine, Inc.
- Hanna Tukachinsky
- Foundation Medicine, Inc.
- Karthikeyan Murugesan
- Foundation Medicine, Inc.
- Kimberly McGregor
- Foundation Medicine, Inc.
- Natalie Danziger
- Foundation Medicine, Inc.
- Dean Pavlick
- Foundation Medicine, Inc.
- Ole Gjoerup
- Foundation Medicine, Inc.
- Jeffrey S. Ross
- Foundation Medicine, Inc.
- Robert Harmon
- Foundation Medicine, Inc.
- Jon Chung
- Foundation Medicine, Inc.
- Brennan Decker
- Foundation Medicine, Inc.
- Lucas Dennis
- Foundation Medicine, Inc.
- Garrett M. Frampton
- Foundation Medicine, Inc.
- Luciana Molinero
- Genentech, Inc.
- Steffi Oesterreich
- Department of Pharmacology and Chemical Biology, University of Pittsburgh
- Jeffrey M. Venstrom
- Foundation Medicine, Inc.
- Geoffrey R. Oxnard
- Foundation Medicine, Inc.
- Priti S. Hegde
- Foundation Medicine, Inc.
- Ethan S. Sokol
- Foundation Medicine, Inc.
- DOI
- https://doi.org/10.1038/s41467-022-35245-x
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 13
Abstract
Liquid biopsies could be valuable tools to monitor breast cancer progression and evolution. Here, the authors investigate genomic profiling of tissue and liquid biopsies in a large cohort of patients with breast cancer during the course of therapy to characterise tumour evolution and acquired mutations.
